Highest-materiality recent filing
Jade Biosciences licenses monospecific antibodies from Paragon for up to $22M in milestones
Paragon grants exclusive worldwide license to undisclosed target antibodies for all human therapeutic areas.
Jade Biosciences prices $150M public offering of 10M shares at $15/share
Priced public offering of 10,000,000 shares of common stock at $15.00 per share for gross proceeds of $150.0M.
Mean IgA reduction ~70% from baseline, sustained at 12 weeks with single 700 mg dose; steady-state simulation supports Q12W dosing.
Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment
Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.
Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026
Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.
Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2
Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.
Jade Biosciences raises $45M in private placement with BB Biotech at $14/share
Private placement of 3,214,286 shares at $14.00 per share for gross proceeds of ~$45M.
Jade Biosciences Q3 net loss $25.2M; cash runway into H1 2028 after $135M placement
Q3 2025 net loss of $25.2M vs $16.3M loss in Q3 2024; R&D expenses $22.0M, G&A $5.4M.
Jade Biosciences raises $135M in PIPE; unveils BAFF-R candidate JADE201
Private placement raises ~$135M gross via 13.37M shares at $9.14 and pre-funded warrants; close expected Oct 8, 2025.
Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3
Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.
Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101
Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.
Jade Biosciences Q1 2025 net loss $38.2M, cash $49.9M, merger closed Apr 28
Net loss of $38.2M for Q1 2025; R&D expenses $20.0M, G&A $3.4M; change in fair value of convertible notes added $15.4M to other expense.
Jade Biosciences completes reverse merger with Aerovate; former Aerovate holders own ~1.4%
Merger closed April 28, 2025; Aerovate stockholders received ~$69.6M special dividend ($2.40 pre-split) and ~1.4% of combined entity.
Aerovate stockholders approve merger with Jade Biosciences, 1-for-35 reverse split
All eight proposals approved at April 16 special meeting, including merger and reverse stock split.
Aerovate discloses stockholder lawsuits and demand letters over merger with Jade Biosciences
Two lawsuits filed March 27, 2025 in NY state court alleging misrepresentations in S-4; seek injunctive relief or damages.
Special cash dividend of $69.6M ($2.40/share) declared, payable to holders of record as of April 25, 2025.
Aerovate announces $67.6-69.6M cash dividend range for proposed merger; stockholder vote April 16
Cash dividend expected $67.6-69.6M in aggregate, based on estimated net cash prior to merger closing.
Aerovate to merge with Jade Biosciences; Jade holders to own 98.4%
Aerovate (AVTE) reverse-merges with Jade; pre-merger Jade stockholders receive 98.4% of combined firm; Aerovate holders receive 1.6%.
Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush
Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.
Aerovate Therapeutics to reduce nearly all workforce after ending AV-101 trial
On June 25, 2024, Aerovate began workforce reduction after ending AV-101 clinical program.
Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial
Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.
Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension
AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.
Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024
Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.
Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024
Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.
Phase 2b portion of IMPAHCT trial enrolled 202 adult patients with PAH.
Aerovate Therapeutics reports Q3 2023 net loss of $19.6M; Phase 2b/3 trial on track for Q2 2024 data
Net loss of $19.6M for Q3 2023, compared to $13.6M in Q3 2022; includes $3.2M stock-based compensation.
Aerovate raises $44.9M via ATM offering; cash runway into 2026
Sold 2,662,721 shares under ATM program for net proceeds of $44.9M.
Aerovate Therapeutics Q1 net loss $16.5M; Phase 2b topline data pushed to Q2 2024
Topline Phase 2b data from IMPAHCT trial of AV-101 now expected in Q2 2024; >100 sites in 20 countries.
Aerovate Therapeutics enters into $75M ATM equity offering with BofA Securities
Entered into ATM Sales Agreement with BofA Securities to sell up to $75M of common stock.
Aerovate reports FY2022 net loss of $51.5M; cash runway into H2 2025
Net loss of $51.5M for FY2022 vs $23.0M in FY2021; R&D expenses $38.6M (up from $15.0M).
Aerovate Q3 net loss widens to $13.6M; trial enrollment delays, cash runway to 2H25
Net loss $13.6M for Q3 2022 vs $6.2M in Q3 2021; R&D expenses tripled to $10.8M.
Aerovate Q1 net loss $10.9M; Phase 2b PAH trial topline data expected Q4 2023/Q1 2024
Net loss Q1 2022 $10.9M vs $2.8M in 2021; R&D up to $7.3M, G&A up to $3.8M.
On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.
On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.
Effective as of July 10, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Habib J. Dable as a member of the Board.
Effective as of January 19, 2023 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), the Board appointed Donald J. Santel as a member of the Board.
the Board appointed Allison Dorval as a member of the Board, effective as of July 15, 2021
Max materiality 1.00 · Median 0.60 · Most common event other_material